Skip to main content

Table 3 Poisson regression incidence rate ratios

From: Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists

 

Crude IRR

Adjusted IRR

95% CI

p

Gender female vs male

1.26

1.37

1.01

1.86

0.042

Age (effect per 10 years)

0.88

0.95

0.86

1.05

0.302

Disease duration 5–9 vs <5 years

0.92

0.67

0.48

0.93

0.016

Disease duration 10+ vs <5 years

0.82

0.61

0.45

0.83

0.002

DMARDs + CS vs DMARDs^

0.87

0.76

0.34

1.68

0.493

Anti-TNFα vs DMARDs^

2.14

1.57

0.55

4.51

0.400

Anti-TNFα + CS vs DMARDs^

4.42

3.60

1.58

8.20

0.002

Anti-TNFα + DMARDs vs DMARDs^

2.92

2.11

0.95

4.71

0.067

Anti-TNFα + DMARDs + CS vs DMARDs^

3.24

2.54

1.15

5.59

0.021

Presence of comorbidities* and smoking

1.22

1.07

0.85

1.37

0.554

Anti-influenza Vaccine

0.84

0.73

0.57

0.94

0.016

Moderate Disease Activity vs Mild at baseline

5.95

4.12

1.24

13.68

0.021

Severe Disease Activity vs Mild at baseline

11.29

4.28

1.21

15.08

0.024

SpA vs RA

0.91

0.96

0.67

1.38

0.817

  1. *presence of at least one of the following comorbidities: COPD, diabetes and leukopenia.
  2. ^DMARDs = control group.
  3. COPD: Chronic Obstructive Pulmonary Disease; CS: Corticosteroids; DMARDs: Disease Modifying Anti-Rheumatic Drugs; RA: Rheumatoid Arthritis; SpA: Spondyloarthropathies; TNF: Tumour Necrosis Factor. IRR:Incidence Rate Ratio, CI: confidence interval.